Previous 10 | Next 10 |
Presentations to highlight two of Castle’s skin cancer gene expression profile tests Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that the c...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that it will release its financial results for the third quarter ended Sept. 30, 2020, after the close of market o...
ConfirmDx-Melanoma is Castle’s gene expression profile test for suspicious pigmented lesions Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced th...
Prospective, multi-center study data support use of DecisionDx ® -Melanoma in T1-T2 melanoma patients 65 years and older to identify those with a low probability of sentinel lymph node positivity Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics...
Presentations highlight DecisionDx-Melanoma and DecisionDx-SCC gene expression profile tests for use in cutaneous melanoma and in cutaneous squamous cell carcinoma Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic infor...
Castle Biosciences (CSTL) announces that Palmetto GBA MolDx, a Medicare Administrative Contractor, has issued a final expanded local coverage determination or LCD for DecisionDx®-Melanoma test. The LCD effective date is Nov. 22, 2020. DecisionDx-Melanoma is a gene expressi...
Palmetto GBA issues final expanded local coverage determination effective November 22, 2020 Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Medic...
Oral presentations to highlight both commercially available skin cancer prognostic tests Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that its data...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the Baird 2020...
Prognostic gene expression profile test for metastatic risk in cutaneous squamous cell carcinoma now available to clinicians in the U.S. Conference Call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personali...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 44 th Annual Growth Conference on Tuesday, Aug. 13, 2024, at ...
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...